sponsored
PatientsVille.com Logo

PatientsVille

Seretide Medical Research Studies

Up-to-date List of Seretide Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Seretide Medical Research Studies

Rank Status Study
1 Unknown  An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive Pulmonary Disease
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: Seretide 500 Accuhaler
Outcome Measures: The primary outcome measures are change in cell type and activation status;   Change in sputum and serum cytokines Change in bacterial colonization
2 Not yet recruiting A Randomized Comparative Effectiveness Research Trial of Three Treatments for COPD Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Salbutamol (Ventolin®);   Drug: Formoterol (Oxis Turbuhaler®);   Drug: Salmeterol / fluticasone (Seretide®);   Drug: Bufei granule;   Drug: Bufeijianpi granule;   Drug: Bufeiyishen granule;   Drug: Yiqizishen granule;   Drug: conventional medicine + TCM
Outcome Measures: the frequency of exacerbation;   Forced expiratory volume in one second;   Dyspnea;   6 Minutes Walking Distance Test(6MWD);   Quality of life;   Economic Evaluation
3 Recruiting Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: salmeterol/fluticasone;   Drug: ipatropium/salbutamol;   Drug: Methylprednisolone;   Drug: Additional broncho-dilators inhalation;   Other: Determining personal target airway resistance;   Device: Ventilator support
Outcome Measures: ∆Raw (the difference between measured and target airway resistance);   Rapidity of ∆Raw change;   number of ventilator-free days from day 1 to 28;   Percentage of breathing without assistance by day 28;   number of episode of nosocomial pneumonia;   Number of total puff of rescue short-acting bronchodilator;   number of drug-related adverse effect;   Mortality rate
4 Recruiting Comparison of Indacaterol 150 μg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 μg/500 μg Twice Daily (b.i.d.)
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol;   Drug: Salmeterol
Outcome Measures: Trough forced expiratory volume in one second (FEV1) at 12 weeks;   Trough FEV1;   FEV1;   FVC;   Standardized AUC (5min-4h) for FEV1;   Transition Dyspnea Index;   COPD Exacerbations;   Mean daily rescue medication use;   Percentage of days with no rescue medication use;   St Georges Respiratory Questionnaire for COPD;   Adverse event data;   ECG;   Vital signs;   Biochemistry, haematology, urinalysis data
5 Unknown  Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: fluticasone/ salmeterol 125/25 mcg/puff;   Drug: fluticasone/ salmeterol 250/25 mcg/puff
Outcome Measures: The change of lung function parameters(FEV1&FVC) at different time points;   Annual rate of acute exacerbations;   Life quality evaluation;   Annual incidence of community-acquired pneumonia
6 Unknown  Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD
Conditions: Chronic Obstructive Pulmonary Disease;   COPD
Interventions: Drug: Combination Fluticasone /Formoterol 12/250 μg;   Drug: Seretide Diskus (salmeterol/fluticasone) 50/250 μg
Outcome Measures: Changes in pre-bronchodilator forced expiratory volume in first second (FEV1);   Changes in forced expiratory volume in first second, without bronchodilator;   Safety descriptive about occurence of adverse events, evaluation of results of clinical/physical examination and laboratory tests results;   Changes in COPD Assessment Test (CAT)
7 Recruiting Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Aclidinium Bromide / Formoterol Fumarate;   Drug: Salmeterol / Fluticasone
Outcome Measures: Peak forced expiratory volume in one second (FEV1) at week 24;   Transition Dyspnoea Index (TDI) focal score at week 24
8 Not yet recruiting Long-Term Safety Evaluation of Dupilumab in Patients With Asthma
Condition: Asthma
Interventions: Drug: dupilumab SAR231893 (REGN668);   Drug: fluticasone propionate and salmeterol;   Drug: budesonide and formoterol;   Drug: mometasone furoate and formoterol
Outcome Measures: Number of participants with adverse events;   Assessment of safety parameters (laboratory data, electrocardiogram and vital signs) - clinically significant changes from baseline;   Forced expiratory volume in one second - clinically significant changes from baseline;   Asthma control questionnaire - clinically significant changes from baseline;   Asthma symptom scores - clinically significant changes from baseline;   Asthma Quality of Life Questionnaire (AQLQS) - clinically significant changes from baseline;   Anti-drug antibodies - changes from baseline;   Biomarkers - changes from baseline
9 Recruiting Stepping Down of Asthma Medication in Controlled Asthma
Condition: Asthma
Intervention: Drug: Asthma medication reduction
Outcome Measures: Asthma exacerbation;   The proportion of asthma patients able to reduce their medication
10 Unknown  The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Salmeterol/Fluticasone Propionate
Outcome Measures: pre-broncholidator FEV1;   post-broncholidator FEV1;   Morning PEF, inspiration capacity (IC) and Residual Volume (RV);   Overall daytime symptom score, reliever medication use,SGRQ and BODY index;   Percent of symptom-free nights, sleep symptoms, nighttime awakenings due to respiratory symptoms;   Biomarkers: serum Clara cell 16 (CC-16) protein and serum surfactant protein D (SPD);   participants with adverse events and COPD exacerbations
11 Not yet recruiting Beta Blocker Therapy in Moderate to Severe COPD
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Biological: Carvedilol;   Biological: Bisoprolol;   Biological: Beclometasone/formoterol;   Biological: Tiotropium;   Biological: Beclometasone
Outcome Measures: Change in airway resistance at 5HZ (R5) using impulse oscillometry from baseline.;   Change in remaining impulse oscillometry measurements from baseline;   Change in spirometry measurements from baseline;   Change in echocardiogram parameters from baseline;   Change in vital signs from baseline;   Change in six minute walk test distance from baseline;   Change in St George's Respiratory Questionnaire score from baseline

These studies may lead to new treatments and are adding insight into Seretide etiology and treatment.

A major focus of Seretide research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Seretide